Therapeutic banner
Therapeutic banner

Transthyretin (ATTR) Amyloidosis

View the latest scientific data presented at congress events in the past 2 years and discover peer-reviewed publications related to ATTR Amyloidosis.
The information on this page pertains to select congress and publication resources. It is not intended to serve as a comprehensive list of all congress and publications resources.

Explore Therapeutic Areas

Publications

View More Arrow

Transthyretin Amyloidosis (ATTR)

Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review

Journal of Comparative Effectiveness Research

Author(s)

Jose Nativi-Nicolau, Ali Yilmaz, Noel Dasgupta, et al

June 2024

Transthyretin Amyloidosis (ATTR)

Impact of Baseline Neuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study

Neurology and Therapy

Author(s)

Marco Luigetti, Dianna Quan, John L. Berk, et al

March 2024

Transthyretin Amyloidosis (ATTR)

Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO study

Journal of the Formosan Medical Association

Author(s)

Lin KP, Yang CC, Lee YC, et al

March 2024

Transthyretin Amyloidosis (ATTR)

Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy

European Journal of Heart Failure

Author(s)

Pablo Garcia-Pavia, Martha Grogan, Parag Kale, et al

February 2024

Transthyretin Amyloidosis (ATTR)

Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis

New England Journal of Medicine

Author(s)

Mathew Maurer, Parag Kale, Marianna Fontana, et al

October 2023

Transthyretin Amyloidosis (ATTR)

Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation

Clinical Pharmacokinetics

Author(s)

Prajakta Badri, Bahru Habtemariam, Megan Melch, et al

August 2023